The critical care portfolio includes the Swan Ganz pulmonary artery catheter, minimally invasive sensors, noninvasive cuffs, tissue oximetry sensors, and monitors.
RT’s Three Key Takeaways:
- BD Acquires Edwards Lifesciences’ Critical Care Portfolio: BD has completed the acquisition of Edwards Lifesciences’ critical care product group, rebranding it as BD Advanced Patient Monitoring.
- Expansion of AI-Enabled Technologies: The acquisition adds technologies like the Swan Ganz pulmonary artery catheter, minimally invasive sensors, and AI-driven clinical decision tools, further advancing BD’s capabilities in monitoring and predictive analytics.
- Strategic Leadership and Operations: BD Advanced Patient Monitoring will operate as a separate business unit within BD’s Medical segment, led by Katie Szyman, and will maintain its presence in Irvine, California.
BD (Becton, Dickinson, and Company), a medical technology company, announced it has acquired Edwards Lifesciences’ critical care product group, which will be renamed as BD Advanced Patient Monitoring.
BD Advanced Patient Monitoring expands BD’s portfolio of smart connected care solutions with its monitoring technologies and artificial intelligence (AI)-enabled clinical decision tools. BD Advanced Patient Monitoring’s technologies are often used simultaneously with the BD Alaris Infusion System in the operating room or intensive care units.
BD Advanced Patient Monitoring’s portfolio includes the Swan Ganz pulmonary artery catheter, minimally invasive sensors, noninvasive cuffs, tissue oximetry sensors, and monitors. Its smart technologies are driven by data analytics with machine learning and AI-based predictive and prescriptive algorithms to help clinicians better understand current and future patient conditions and provide clinical decision support tools.
Embracing Advanced Technologies
“The health care industry is being redefined by AI, robotics, and autonomous solutions, and our team continues to accelerate the application of these new technologies to improve the quality and cost of patient care around the world,” says Tom Polen, chairman, chief executive officer and president of BD, in a release. “Today, BD is proud to welcome BD Advanced Patient Monitoring, whose leading technologies, AI-enabled solutions, and strong innovation pipeline expand our portfolio of smart, connected care solutions, create significant value for customers, and put BD at the forefront of enabling the future of health care.”
BD Advanced Patient Monitoring will operate as a separate business unit within BD’s medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif.Â
Katie Szyman, who has served as corporate vice president of the business under Edwards since 2015, has been named worldwide president of BD Advanced Patient Monitoring, reporting to Mike Garrison, executive vice president and president of the BD medical segment.
Photo caption: The critical care product group includes the HemoSphere monitor
Photo credit: BD
